Galapagos has entered into an agreement with MorphoSys to develop therapeutic antibodies from discovery through to Phase IIa clinical trials within the bone and joint disease area. Although Galapagos has a strong level of expertise within the therapy area, this is its first antibody-focused agreement, which makes human antibody company, MorphoSys, an ideal partner for this venture.